Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas (Q37774667)

23 August 2017

1 reference

title

Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas (English)

1 reference

23 August 2017

Takashi Watanabe

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Expert Opinion on Investigational Drugs

23 August 2017

published in

1 reference

23 August 2017

volume

19

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1113-1127

1 reference

Histone deacetylases and cancer: causes and therapies

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

HDAC6 is a microtubule-associated deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Acetylation of importin-alpha nuclear import factors by CBP/p300.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Acetylation of beta-catenin by CREB-binding protein (CBP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

DNA damage-induced translocation of the Werner helicase is regulated by acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Biological effects of bexarotene in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Follicular lymphoma in the United States: first report of the national LymphoCare study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Programmed anuclear cell death delimits platelet life span.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Acetylation inactivates the transcriptional repressor BCL6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Interfering with cellular signaling pathways enhances sensitization to combined sodium butyrate and GCV treatment in EBV-positive tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.504710

10.1517/13543784.2010.504710

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference